
|Videos|January 18, 2023
The Impact of Using AR Pathway Inhibitors and Docetaxel in Early Treatment of Prostate Cancer
Author(s)Stephen J. Freedland, MD
Dr Stephen J. Freedland muses on how the utilization of AR pathway inhibitors and docetaxel in earlier lines of prostate cancer treatment has impacted subsequent treatment selection in mCRPC.
Advertisement
Episodes in this series

Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
NDV-01 produces robust 9-month results in high-risk NMIBC
2
CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC
3
SUO 2025 data confirm IsoPSA accuracy independent of mpMRI use
4
New agents, biomarkers shape recent advances in bladder cancer
5


















